Genmab A/S or Halozyme Therapeutics, Inc.: Who Manages SG&A Costs Better?

Managing SG&A Costs: Genmab A/S vs. Halozyme Therapeutics, Inc.

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and operational efficiency. Over the past decade, Genmab A/S and Halozyme Therapeutics, Inc. have demonstrated contrasting approaches to handling these costs.

From 2014 to 2023, Genmab A/S saw a staggering increase in SG&A expenses, rising from approximately $80 million to over $3.3 billion. This represents a growth of over 4,000%, reflecting the company's aggressive expansion and investment in administrative capabilities. In contrast, Halozyme Therapeutics, Inc. maintained a more conservative growth in SG&A expenses, increasing from around $36 million to $149 million, a more modest 314% rise.

This data highlights Genmab's expansive strategy, while Halozyme's approach suggests a focus on cost containment. Investors and industry analysts should consider these trends when evaluating the companies' financial health and strategic priorities.